Study of HSK44459 for Behçet's disease with mouth ulcers
Treatments studied
Part of Immune system & allergy clinical trials.
This trial tests an experimental pill, HSK44459, for people with Behçet's disease who have frequent mouth ulcers. It aims to see if the drug can safely reduce ulcer episodes and improve symptoms.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have been diagnosed with Behçet's disease and have had at least 3 episodes of mouth ulcers in the past year, with at least 2 mouth ulcers present during screening.
- You have previously received treatment for Behçet's disease and are eligible for systemic therapy for mouth ulcers.
- You do not have active involvement of major organs (like lungs, brain, eyes, stomach, or blood vessels) from Behçet's disease that would need strong immune-suppressing treatment.
- You have not used certain immune-suppressing medications (e.g., colchicine, tofacitinib, methotrexate, biologics) or strong drug-interacting medications within specific time windows before the trial starts.
- Your lab test results (like kidney function, liver function, and blood counts) meet the trial's safety limits.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new pill called Hemay005 for adults with Behçet's disease who have at least two mouth sores that need treatment beyond creams or rinses. It aims to see if the drug safely reduces mouth ulcers.
This trial is for people who have already completed a prior study of the drug HSK44459 for Behçet's disease. It will continue to monitor the safety and effects of the drug over a longer period.
This trial studies lenalidomide to treat frequent, ongoing mouth ulcers caused by mucosal Behçet’s syndrome. It’s meant for people whose mouth sores keep coming back despite standard treatments like steroid medicines and other immune-suppressing drugs.
This study tests if ustekinumab or apremilast can help control Behçet's disease symptoms like mouth and genital ulcers, skin sores, and joint pain. It may be an option if standard treatments haven't worked well.
This study tests apremilast to help reduce active, recurring mouth (oral) ulcers in children with Behçet’s disease. It may help if your child has had repeated mouth ulcers despite at least one non-biologic treatment.
This Phase 2 trial tests tocilizumab and tofacitinib to see if they can better control vascular (blood-vessel) Behçet’s syndrome. It may help by lowering inflammation and reducing complications from aneurysms in the aorta or peripheral arteries.
Hear when a new Behcet's Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.